Maribavir Synthesis and Crystallization for Yield and Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing syntheses of maribavir, an antiviral medication for CMV infection, suffer from low overall yields and impurities, which affect the quality and safety of the drug product.
Innovation Solution
An improved synthesis of maribavir is developed, involving optimized reaction conditions and crystallization processes to enhance yield and purity, with specific attention to controlling impurities and achieving a desired polymorphic form (Form VI) for better bioavailability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods are used, then maribavir can be produced, but the overall yield is low (27-49%) and impurities are generated
Solution Approach 1:
The synthesis is divided into discrete modular steps with intermediate purification. Each reaction step is optimized independently, and intermediates are purified to remove impurities before proceeding to the next step, preventing impurity accumulation and maximizing overall yield.
Solution Approach 2:
Protecting groups are installed on the ribofuranose moiety before glycosylation to prevent side reactions and ensure high stereoselectivity for the beta-anomer. This preliminary protection strategy prevents formation of unwanted isomers and simplifies subsequent purification.
2Manufacturing precision
If multiple synthesis steps are performed, then maribavir structure is achieved, but the process complexity increases and yield decreases
Solution Approach 1:
Reaction conditions are precisely controlled including temperature, solvent composition, and reagent ratios to optimize each transformation step. The glycosylation is performed under specific conditions to achieve high beta-selectivity, and crystallization parameters are optimized to obtain the desired polymorphic form.
Solution Approach 2:
Protecting groups serve as intermediaries that temporarily modify the ribofuranose molecule to enable selective glycosylation. These protecting groups are strategically chosen to facilitate the reaction and are subsequently removed under mild conditions to give the final product.
3Productivity
If alpha anomer is formed in the first step, then byproduct is generated, but separation and purification become necessary
Solution Approach 1:
Protecting groups are installed on the ribofuranose before glycosylation to control the stereochemistry of the reaction. This preliminary structural modification directs the formation of the beta-anomer and prevents alpha-anomer formation, eliminating the need for separation.
Solution Approach 2:
The patent utilizes crystallization to separate the desired beta-anomer from the alpha-anomer based on their different solubility and crystallization properties. The beta-anomer crystallizes in a specific polymorphic form that can be selectively obtained through controlled crystallization conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved synthesis achieves yields of at least 45% and minimizes impurities, ensuring consistent drug quality and safety, thereby enhancing the efficacy and safety of maribavir formulations.
Implementation Method 1
The reaction mixture is cooled to a temperature between about 20° C. and about 40° C. and allowed to stand for a period of time to crystallize compound 2
Implementation Method 2
The solid which forms is collected by filtration
Implementation Method 3
The solid is washed with a solvent or mixture of solvents
Implementation Method 4
The solid is dried in vacuo
Data Source
AI summary
The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir.